Grex, Inc. (GRANULES) received approval on December 16, 2024, for its Abbreviated New Drug Application (ANDA219258), unleashing significant pricing pressure on the market for the specific product. The clearance provides the company with an immediate entry point and the potential to capture market share through generic competition.